Published 4 years ago • loading... • Updated 4 years ago
New combined therapy helps extend lives of men with prostate cancer
Summary by Ground News
A combination of androgen deprivation therapy and pelvic lymph node radiation kept nearly 90% of clinical trial patients at bay for five years. The findings were published in the peer-reviewed journal The Lancet. Prostate cancer is the most common non-skin cancer in the U.S., affecting 1 in every 6 to 7 men.